1-(2-Phenanthrenylcarbonyl)-2,3-piperazinedicarboxylic acid | 1202172-03-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 菲及其衍生物
• 英文名称: 1-(2-Phenanthrenylcarbonyl)-2,3-piperazinedicarboxylic acid
• 英文别名: 1-(phenanthrene-2-carbonyl)piperazine-2,3-dicarboxylic acid
• CAS: 1202172-03-9
• 化学式: C₂₁H₁₈N₂O₅
• 分子量: 378.4
• InChiKey: IWWXIZOMXGOTPP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  28
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  107
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• Phenanthryl piperazinyl dicarboxylic acids as selective nmda receptor modulating agents
  申请人：——

  公开号：US20030078237A1

  公开（公告）日：2003-04-24

  Disclosed are compounds of formula (I) wherein: L is (a) optionally substituted by replacement of one or more of the hydrogen atoms on the phenanthrene ring system by one or more groups other than hydrogen; A is CH 2 , SO 2 or C═O; X is CO 2 H, PO 3 H 2 , PO 2 H 2 , PO 2 HR 5 , PO 2 HOR 5 , SO 3 H, SO 2 H, or tetrazole; and R 1 , R 2 , R 3 , R 4 and R 5 are independently selected from H, alkyl, alkenyl, alkynyl, aryl and aralkyl; or a pharmaceutically acceptable acid salt or base addition salt or an in vivo hydrolysable ester or amide thereof. Compounds of formula (I) are selective NMDA receptor modulating agents and, therefore, may be used to advantage in vitro in neuroassays and in vivo in the treatment of disorders of the CNS.

  公开了化合物的结构式(I)，其中：L是(a)通过将菲环上的一个或多个氢原子替换为一个或多个非氢基团而选择性地取代的；A是CH2，SO2或C═O；X是CO2H，PO3H2，PO2H2，PO2HR5，PO2HOR5，SO3H，SO2H或四唑；R1、R2、R3、R4和R5独立地选择自H、烷基、烯基、炔基、芳基和芳基烷基；或其药学上可接受的酸盐或碱加合盐或体内可水解的酯或酰胺。结构式(I)的化合物是选择性NMDA受体调节剂，因此，在神经分析中和中枢神经系统疾病的治疗中可以得到优势应用。
• KETAMINE FORMULATIONS
  申请人：Otonomy, Inc.

  公开号：EP2932971A1

  公开（公告）日：2015-10-21

  Formulations of ketamine for administration to the inner or middle ear.

  用于内耳或中耳给药的氯胺酮制剂。
• Nanocarriers and their processing for diagnostics and therapeutics
  申请人：Rhode Island Hospital

  公开号：US10555948B2

  公开（公告）日：2020-02-11

  The compositions and methods of the invention provide compositions and methods for preferential targeting of tissues to delivery therapeutic or diagnostic agents. For example, such compounds are useful in the treatment of joint disorders those affecting articulating joints, e.g., injury-induced osteoarthritis as well as autoimmune diseases affecting joint tissue such as rheumatoid arthritis.

  本发明的组合物和方法提供了优先靶向组织递送治疗或诊断制剂的组合物和方法。例如，这类化合物可用于治疗影响关节的关节疾病，如损伤引起的骨关节炎以及影响关节组织的自身免疫性疾病，如类风湿性关节炎。
• Modulation of NMDA receptor currents via orexin receptor and/or CRF receptor
  申请人：Bartlett Selena

  公开号：US20060178307A1

  公开（公告）日：2006-08-10

  This invention pertains to the discoveries that orexin and/or CRF increase NMDAR (N-methyl-D-aspartate receptor)-mediated currents at excitatory synapses onto a subset of dopamine cells in the ventral tegmental area (VTA) in the mammalian brain. The orexin effect can be blocked by an orexin receptor type 1 (OXR1). The CRF effect can be blocked by a CRF receptor 2 (CRF-R2) antagonist or by an inhibitor of the CRF-binding protein (CRF-BP). Methods are provided that exploit these discoveries to modulate NMDAR-mediated currents in vivo and in vitro and to screen for modulators (upregulators or downregulators) of NMDA-mediated currents. In vivo methods include the use of modulators of the orexin and CRF pathways to of mitigate a symptom of substance abuse. The invention also provides methods and compositions for co-administration of modulators that act via the orexin and CRF pathways.

  本发明发现，在哺乳动物大脑腹侧被盖区（VTA）多巴胺细胞亚群的兴奋性突触上，奥曲肽和/或 CRF 可增加 NMDAR（N-甲基-D-天冬氨酸受体）介导的电流。奥曲肽效应可被奥曲肽受体 1 型（OXR1）阻断。CRF 效应可被 CRF 受体 2（CRF-R2）拮抗剂或 CRF 结合蛋白（CRF-BP）抑制剂阻断。本文提供的方法利用了这些发现来调节体内和体外 NMDAR 介导的电流，并筛选出 NMDA 介导电流的调节剂（上调剂或下调剂）。体内方法包括使用奥曲肽和 CRF 通路的调节剂来减轻药物滥用的症状。本发明还提供了联合施用通过奥曲肽和 CRF 途径起作用的调节剂的方法和组合物。
• PHENANTHRYL PIPERAZINYL DICARBOXYLIC ACIDS AS SELECTIVE NMDA RECEPTOR MODULATING AGENTS
  申请人：UNIVERSITY OF NEBRASKA BOARD OF REGENTS

  公开号：EP1244638A2

  公开（公告）日：2002-10-02